The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD.

Phase 4Not Yet RecruitingNCT07289750

The Fourth Affiliated Hospital of Zhejiang University School of Medicine80 enrolled

Overview

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

T2DM MAFLD

Interventions

combination treatmentDRUG

combination of alogliptin and actoplus met

alone treatmentDRUG

actoplus met

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1.Meet the T2DM diagnosis criteria of China's Diabetes Prevention and Control Guidelines (2024 Edition) 2.Meet the MAFLD diagnosis criteria of Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024) 3.HbA1c: 6.5-9.5%，BMI: 19-35 kg/m2。 4.No hypoglycemic drugs or insulin have been used within half a year. Exclusion Criteria: * 1.Severe infections, surgeries and other stressful situations. 2.Other types of diabetes. 3.Severe cardiovascular, brain, liver and kidney disorders. 4.Acute complications of diabetes. 5.Malignant tumor

Outcomes

Primary Outcomes

hemoglobin A1c

Time frame: after 6 months of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.